Sana Biotechnology, Inc. announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023 in Orlando, FL.
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.
Late-breaking poster details:
| Title: | Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells |
| Session Title: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Session Date: | Wednesday, April 19, 2023 |
| Session Time: | 9:00 a.m. - 12:30 p.m. ET |
| Location: | Poster Section 35 |
| Abstract Number: | LB311 |
Poster details:
| Title: | Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Gene and Vector-based Therapy |
| Session Date: | Monday, April 17, 2023 |
| Session Time: | 1:30 p.m. - 5:00 p.m. ET |
| Location: | Poster Section 16 |
| Abstract Number: | 2734 |
| Title: | Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Gene and Vector-based Therapy |
| Session Date: | Monday, April 17, 2023 |
| Session Time: | 1:30 p.m. - 5:00 p.m. ET |
| Location: | Poster Section 16 |
| Abstract Number: | 2735 |
| Title: | Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge |
| Session Category: | Immunology |
| Session Title: | CAR T-cell Therapy 2 |
| Session Date: | Tuesday, April 18, 2023 |
| Session Time: | 9:00 a.m. - 12:30 p.m. ET |
| Location: | Poster Section 23 |
| Abstract Number: | 4091 |
Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 2023 American Association for Cancer Research Annual Meeting; expectations for the Company’s presentations at such meeting, including the content of such presentations; and expectations for the publication of abstracts. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
